1 recruiting, 1 unknown. 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Nevus, Blue: new trials by email Literature Review of Nevus, Blue trials Research Report on Nevus, Blue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice - Advanced Melanoma | Phase 3 | Recruiting | Immunocore Ltd | 540 | 2022-12-19 | 2026-02-25 |
| Atypical MOLes and Melanoma Early Detection Study (MoleMed) Non-invasive adhesive system (patch) - Melanoma, Melanoma (Skin) | Not applicable | Unknown | Russian Academy of Medical Sciences | 350 | 2020-04-01 | 2022-06-14 |
Melanoma (2) · Dysplastic Nevus Syndrome (1) · Nevus (1) · Nevus, Epithelioid and Spindle Cell (1) · Nevus, Pigmented (1) · Nevus, Spindle Cell (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Skin Diseases (2) · Skin Neoplasms (2) · Skin and Connective Tissue Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Neoplastic Syndromes, Hereditary (1) · Nevus (1)
Transdermal Patch (1) · pembrolizumab (1) · tebentafusp (1)
Immunocore Ltd (1) · Russian Academy of Medical Sciences (1)
Australia (1) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Russia (1) · Spain (1) · Switzerland (1) · United Kingdom (1) · United States (1)